The latest biotech news

News and Trends 30 Nov 2015

Heptares’ G-Protein StaR Platform has now Hooked Pfizer in a Billion Euro Deal

Heptares Therapeutics from the UK has landed Pfizer in a huge potential $1.9Bn deal for their G-protein receptor platform. Heptares Therapeutics was founded by Fiona Marshall (one of our Top 10 UK Women in Biotech), who now serves as a CSO to Japanese Big boss Sosei, which wholly acquired Heptares earlier this year in a […]

November 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 30 Nov 2015

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

CAR-T is solidifying in everybody’s mind as the next revolution in Cancer treatment. But there is still a lot to do…That’s basically what came out from my discussion with André Choulika, the CEO of the French CAR-T miracle Cellectis. Cellectis is probably the most successful Biotech in France. It was founded in 1999 by Choulika […]

November 30, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 30 Nov 2015

How Wearable Electronics Will Change Clinical Trials?

In collaboration with ClinCapture Advances in sensor technology and microelectronics have opened new opportunities in the health and life sciences industries. Wearable sensors allow for continuous bio-monitoring without any manual intervention, thus reducing provider-patient interaction and costs while contributing improvements in the quality of the data. Wearable electronics, or wearables in short, are light electronics with embedded […]

November 30, 2015 - 5 minutesmins - By Glenn Keet

News and Trends 28 Nov 2015

What happened this week? Boston Pharmaceuticals, Biosimilars, Adaptimmune

Monday: First Investment by the Former CEO of Sanofi? Just a €560M Virtual Biotech… #Easy Tuesday: 2015 Review: What Exciting Developments Have Been Made in Neurodegenerative Disease? Wednesday: Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War! Thursday: A €1.3M Start-Up is Engineering Baker’s Yeast to Make Green House Gases Useful Friday: Could this new […]

November 28, 2015 - 1 minutemin - By Philip Hemme

regeneron sanofi praulant odyssey alirocumab cardiac statins

News and Trends 27 Nov 2015

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Sanofi & Regeneron have completed enrollment in the global Phase III for Praulent (alirocumab), which is evaluating its potential cardiovascular benefits for patients with acute coronary syndrome (ACS). The ‘Odyssey Outcomes’ Study has enrolled around 18,000 patients for its trial (phwoar), and if it shows positive results could be a huge success for Sanofi and […]

November 27, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 27 Nov 2015

Could this new TCR Lung Cancer Trial Save Adaptimmune from a Volatile Stock Situation?

Adaptimmune has initiated a phase I/II safety and tolerability study of its affinity enhanced T-cell therapy targeting the NY-ESO-1 cancer antigen in patients with non-small cell lung cancer (NSCLC). Adaptimmune is developing the affinity enhanced T-cell therapy targeting the NY-ESO-1 antigen under a collaboration agreement with GlaxoSmithKline (GSK). Located in Oxford (UK) this clinical stage […]

November 27, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 27 Nov 2015

Biotech of the week: PsiOxus, “non-traditional” Immuno-oncology from Oxford

This week we leave Ireland and head South-East across the Irish Sea where we arrive at the ancient city of Oxford, our location of interest. ‘The city of dreaming spires’ is known for it’s world famous university, the Shark House (if you don’t know it, have a search, you won’t regret it :p) and the location for […]

November 27, 2015 - 2 minutesmins - By Philip Hemme

twb greentech yeast enobraq carbon hydrocarbon

News and Trends 26 Nov 2015

A €1.3M Start-Up is Engineering Baker’s Yeast to Make Green House Gases Useful

Culturing yeast cells to absorb CO2 could be the Green way forward for this new French Start-up. As a spin off Toulouse White Biotechnologies (TWB) project, the seed investor in its €1.3M Green Seed Fund is the lead French VC Sofinnova. TWB, a pre-industrial demonstrator in the field of industrial biotechnology managed by INRA (the […]

November 26, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Ablynx – the Belgian Nanobody biotech (which uses monoclonal antibodies of Alpacas) has entered a new and exclusive partnership with the Danish Novo Nordisk on a mysterious disease… Ablynx are famously well connected in the biotech industry, with many huge pharmas licensing out their Alpaca-nanobody tech. Partnerships include AbbVie (Immunology), Boehringer Ingelheim, Genzyme (Multiple Sclerosis/CNS), […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

The UK-Israeli €378M Small-Molecule Offensive Against Migraines

The Israeli TEVA and UK Heptares Therapeutics (now owned by Japanese Sosei) have partnered up on novel drug therapies targeting Migraines. The pain and disruption migraines can cause pain that lasts from 4 to 72 hours, and around 10 million worldwide suffer such episodes on a regular basis. Signs and symptoms of a migraine include photosensitivity […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

biosimilar war neulasta herceptin avastin rituxan1

News and Trends 25 Nov 2015

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Novartis is hitting back in the Biosimilar battleground: now Neulasta, the white blood cell booster for Cancer, is the latest of Amgen’s victims… Neulasta (pegfilgrastim) has been submitted through Novartis’ subsidiary, Sandoz. As a recombinant human granulocyte colony-stimulating factor (G-CSF), pegfilgrastim looks to stimulate the immune system and boost the white cell count. Neulasta is […]

November 25, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 25 Nov 2015

Why Biotech Companies Should Care About Native Advertising?

Biotech companies are constantly trying to reach consumers online, competing to grab a few minutes of their attention. Native Advertising is opening new opportunities for biotech companies to advertise online. Most of the marketing budgets are moving online. While display ads (banners) were the golden standard for a long time, this practice is rapidly changing. […]

November 25, 2015 - 4 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Heptares’ G-Protein StaR Platform has now Hooked Pfizer in a Billion Euro Deal

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

How Wearable Electronics Will Change Clinical Trials?

What happened this week? Boston Pharmaceuticals, Biosimilars, Adaptimmune

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Could this new TCR Lung Cancer Trial Save Adaptimmune from a Volatile Stock Situation?

Biotech of the week: PsiOxus, “non-traditional” Immuno-oncology from Oxford

A €1.3M Start-Up is Engineering Baker’s Yeast to Make Green House Gases Useful

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

The UK-Israeli €378M Small-Molecule Offensive Against Migraines

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Why Biotech Companies Should Care About Native Advertising?

Subscribe to our newsletter to get the latest biotech news!